



Imricor and MiRTLE Medical Announce Joint Development Agreement to Deliver 12-Lead ECG for Real-Time MRI-guided Cardiac Ablations



Minneapolis, MN – November 02, 2017- Imricor and MiRTLE Medical announce a joint development agreement to fully integrate MiRTLE’s MR compatible 12-lead ECG system with Imricor’s Advantage-MRTM EP Recorder/Stimulator System. This integration, along with Imricor’s MR compatible catheters, will allow physicians to perform complex cardiac ablations, such as for treating ventricular tachycardia and atrial fibrillation, under real-time MRI-guidance.

“This is exciting news,” said Philipp Sommer, MD, electrophysiologist at the Helios Heart Center in Leipzig, Germany. “Ablations to treat complex cardiac arrhythmias could benefit from the use of real-time MR imaging and these arrhythmias require 12-lead ECG monitoring during the procedure. This integration is a critical step towards realizing the full potential of MR-guided electrophysiology.”

Ablations guided by real-time MRI address the fundamental limitations of conventional x-ray guided procedures. Unlike x-ray imaging, MRI allows physicians to visualize soft tissue structures. During MRI-guided ablations, physicians can see the heart and visualize and assess lesion formation to identify inadequate or incomplete ablation lines. These benefits have the potential to make procedures faster, safer, and more effective – all in an environment that is free of ionizing radiation.

About MiRTLE Medical LLC

MiRTLE Medical is a privately funded medical device company founded in 2012. MiRTLE Medical designs and manufactures MRI-compatible 12-lead ECG monitors and software to enable cardiac monitoring inside an MRI to expand clinical and operational procedures to improve patient outcomes.

MiRTLE Medical LLC

1600 Osgood St. • Suite 2017 • North Andover, MA 01845 • 978.918.7223 • mirtlemed.com